TESARO, Inc. (TSRO) Stock Rating Reaffirmed by HC Wainwright
TESARO, Inc. (NASDAQ:TSRO)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a note issued to investors on Monday. They presently have a $158.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 85.69% from the company’s previous close.
TSRO has been the topic of several other reports. Robert W. Baird reaffirmed a “hold” rating and set a $120.00 target price on shares of TESARO in a research note on Friday, November 10th. Wedbush reaffirmed an “outperform” rating and set a $160.00 target price on shares of TESARO in a research note on Monday, September 11th. Leerink Swann raised shares of TESARO from a “market perform” rating to an “outperform” rating in a research note on Wednesday, November 15th. Barclays PLC began coverage on shares of TESARO in a research note on Monday, October 23rd. They set an “equal weight” rating and a $135.00 target price on the stock. Finally, Zacks Investment Research raised shares of TESARO from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $161.72.
Shares of TESARO (NASDAQ TSRO) traded down $0.81 on Monday, reaching $85.09. 371,007 shares of the company traded hands, compared to its average volume of 1,031,102. TESARO has a 1 year low of $84.42 and a 1 year high of $192.94. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34.
ILLEGAL ACTIVITY WARNING: “TESARO, Inc. (TSRO) Stock Rating Reaffirmed by HC Wainwright” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/11/20/tesaro-inc-tsro-stock-rating-reaffirmed-by-hc-wainwright.html.
In related news, VP Edward C. English sold 10,862 shares of the stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the completion of the sale, the vice president now owns 6,258 shares in the company, valued at approximately $844,329.36. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Grant C. Bogle sold 14,167 shares of the stock in a transaction on Friday, September 1st. The stock was sold at an average price of $135.00, for a total transaction of $1,912,545.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 35,692 shares of company stock valued at $4,628,976. 34.60% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of the stock. Janus Henderson Group PLC acquired a new stake in shares of TESARO in the 2nd quarter worth $100,301,000. PointState Capital LP acquired a new stake in shares of TESARO in the 2nd quarter worth $85,971,000. TimesSquare Capital Management LLC acquired a new stake in shares of TESARO in the 3rd quarter worth $33,911,000. Pictet Asset Management Ltd. lifted its stake in shares of TESARO by 58.1% in the 3rd quarter. Pictet Asset Management Ltd. now owns 630,904 shares of the biopharmaceutical company’s stock worth $81,450,000 after acquiring an additional 231,799 shares during the period. Finally, Pioneer Investment Management Inc. lifted its stake in shares of TESARO by 195.6% in the 2nd quarter. Pioneer Investment Management Inc. now owns 317,753 shares of the biopharmaceutical company’s stock worth $44,441,000 after acquiring an additional 210,273 shares during the period.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.